Financials Orthocell Limited

Stocks

Delayed Australian S.E. Other stock markets 09:49:52 18/06/2026 am IST			5-day change	1st Jan Change
0.7650 ^AUD	-0.65%		+2.68%	-29.49%

30/04	Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada	MT
28/04	Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%	MT

Fiscal Period: June	2022	2025	2026	2027	2028
Net sales ¹	-	-	12.55	23.55	44.65
Change	-	-	-	87.65%	89.6%
EBITDA ¹	-	-	-11.6	-7.3	0.5
Change	-	-	-	37.07%	106.85%
EBIT ¹	-	-	-12.4	-8.35	-1.35
Change	-	-	-	32.66%	83.83%
Interest Paid	-	-	-	-	-
Earnings before Tax (EBT) ¹	-	-	-11.4	-5.1	2.4
Change	-	-	-	55.26%	147.06%
Net income ¹	-9.107	-8.567	-12.5	-7.85	-1.45
Change	-	-	-45.91%	37.2%	81.53%
Announcement Date	30/08/22	29/08/25	-	-	-

¹AUD in Million

Estimates

Fiscal Period: June	2026 S1	2026 S2	2027 S1	2027 S2
Net sales ¹	5.417	7.15	10	12.8
Change	-	31.98%	39.86%	28%
EBITDA ¹	-	-7	-1.8	-3.8
Change	-	-	74.29%	-111.11%
EBIT ¹	-6.024	-7.5	-4	-4.5
Change	-	-24.5%	46.67%	-12.5%
Charge d'intérêts	-	-	-	-
Earnings before Tax (EBT) ¹	-	-6.2	-1.5	-3.6
Change	-	-	75.81%	-140%
Net income ¹	-	-7.5	-1.5	-3.6
Change	-	-	80%	-140%
Announcement Date	23/02/26	-	-	-

¹AUD in Million

Estimates

Fiscal Period: June	2022	2025	2026	2027	2028
Net Debt ¹	-	-	-42.8	-28.8	-21.8
Change	-	-	-	32.71%	24.31%
Announcement Date	30/08/22	29/08/25	-	-	-

¹AUD in Million

Estimates

Fiscal Period: June	2026	2027	2028
CAPEX ¹	0.5	3.3	3.35
Change	-	560%	1.52%
Free Cash Flow (FCF) ¹	-12.9	-13.15	-11.4
Change	-	-1.94%	13.31%
Announcement Date	-	-	-

¹AUD in Million

Estimates

Fiscal Period: June	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-	-	-	-	-92.43%	-31%	1.12%
EBIT Margin (%)	-	-	-	-	-98.8%	-35.46%	-3.02%
EBT Margin (%)	-	-	-	-	-90.84%	-21.66%	5.38%
Net margin (%)	-	-	-	-	-99.6%	-33.33%	-3.25%
FCF margin (%)	-	-	-	-	-102.79%	-55.84%	-25.53%
FCF / Net Income (%)	-	-	-	-	103.2%	167.52%	786.21%
Profitability
ROA	-	-	-	-	-24%	-16%	-2.3%
ROE	-	-	-	-	-24%	-16%	0.2%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	3.98%	14.01%	7.5%
CAPEX / EBITDA (%)	-	-	-	-	-4.31%	-45.21%	670%
CAPEX / FCF (%)	-	-	-	-	-3.88%	-25.1%	-29.39%
Items per share
Cash flow per share ¹	-	-	-	-	-0.05	-0.02	0.01
Change	-	-	-	-	-	60%	150%
Dividend per Share ¹	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	0.13	0.12	0.14
Change	-	-	-	-	-	-7.69%	16.67%
EPS ¹	-0.047	-	-	-0.038	-0.04	-0.02	0.01
Change	-	-	-	-	-5.26%	50%	150%
Nbr of stocks (in thousands)	1,97,128	-	-	2,43,344	2,72,254	2,72,254	2,72,254
Announcement Date	30/08/22	-	-	29/08/25	-	-	-